Sign in Subscribe

metastatic

A collection of 142 issues

Preclinical study shows fruquintinib combined with TAS-102 has antitumor activity in colorectal and gastric cancer models

Skip to content The CRC Digest ▸ TREATMENT Preclinical study shows fruquintinib combined with TAS-102 has antitumor activity in colorectal and gastric cancer models Fruquintinib, an oral inhibitor of all three vascular endothelial growth factor receptors that has been approved for chemorefractory CRC, showed combined antitumor activity with TAS-102 in xenograft

Immunotherapy produces durable responses in dMMR/MSI-H metastatic CRC patients with poor performance status

Skip to content The CRC Digest ◆ TRIAL DATA Immunotherapy produces durable responses in dMMR/MSI-H metastatic CRC patients with poor performance status Research shows that patients with deficient mismatch repair or high microsatellite instability can benefit from immunotherapy even when they have poor performance status, a group often excluded from

CRC Research Update — July 30, 2026

Today's colorectal cancer research highlights

Liquid biopsy may guide HER2-targeted therapy rechallenge in metastatic disease

Skip to content The CRC Digest ▸ TREATMENT Liquid biopsy may guide HER2-targeted therapy rechallenge in metastatic disease Real-world data suggest that monitoring HER2 amplification through liquid biopsy can help identify patients with HER2-amplified metastatic colorectal cancer who may benefit from rechallenge with anti-HER2 therapy. (JCO Precision Oncology) This content is

Phase III trial tests chemotherapy plus immunotherapy in MSI-H metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Phase III trial tests chemotherapy plus immunotherapy in MSI-H metastatic colorectal cancer The phase III COMMIT trial randomly assigned first-line mismatch repair-deficient metastatic colorectal cancer patients in a three-arm study comparing mFOLFOX6/bevacizumab/atezolizumab versus atezolizumab monotherapy, testing whether adding chemotherapy to

Dual Immune Checkpoint Blockade Shows Early Survival Benefit in MSI-H Metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA Dual Immune Checkpoint Blockade Shows Early Survival Benefit in MSI-H Metastatic CRC Research comparing dual CTLA-4/PD-1 blockade versus anti–PD-1 alone in MSI-H (microsatellite instability-high) metastatic colorectal cancer. (Clinical Colorectal Cancer) This content is informational only and does not constitute medical

ESMO Updates Guidelines for Metastatic Colorectal Cancer

Skip to content The CRC Digest ● REGULATORY ESMO Updates Guidelines for Metastatic Colorectal Cancer New ESMO Clinical Practice Guidelines establish structured treatment algorithms driven by MMR/MSI status, ECOG performance, tumor location, and extended molecular profiling including RAS, BRAF, HER2, and KRAS G12C. Key updates include first-line FOLFOX-encorafenib-cetuximab for BRAF

CRC Research Update — July 25, 2026

Today's colorectal cancer research highlights

RAS and BRAF mutations may predict different immunotherapy outcomes in MSI-H/dMMR metastatic CRC

Skip to content The CRC Digest ◇ RESEARCH RAS and BRAF mutations may predict different immunotherapy outcomes in MSI-H/dMMR metastatic CRC A meta-analysis found that oncogenic driver mutations like RAS and BRAF may contribute to clinically meaningful differences in how MSI-H/dMMR metastatic colorectal cancer responds to immune checkpoint inhibitors,

CRC Research Update — July 24, 2026

Today's colorectal cancer research highlights